By: IPP Bureau
Last updated : August 09, 2021 9:30 am
India business contributes to a stellar performance
The company has reported a total income of Rs.5569.28 crores during the period ended June 30, 2021, as compared to Rs.4666.58 crores during the period ended March 31, 2021. During the period ended June 30, 2020, the total income was Rs 4411.61 crore
The company has posted net profit of Rs.714.72 crores for the period ended June 30, 2021, as against net profit of Rs.413.38 crores for the period ended March 31, 2021. The company posted a net profit/(loss) of Rs 577.91 crore for the period ended June 30, 2020.
The company has reported EPS of Rs.8.85 for the period ended June 30, 2021, as compared to Rs.5.12 for the period ended March 31, 2021. The EPS for the period ended June 30, 2020, stood at Rs 7.16 crore
Commenting on the results, Umang Vohra, MD and Global CEO, Cipla, "I am pleased to see the robust demand led traction in core therapies across our branded markets and continued cost control leading to 27% revenue growth and 24.5% EBITDA margin for the quarter.”
He further added, "In India, we maintained our market-beating performance as core therapies responded to demand triggers along with support from Covid portfolio during the second wave. I am delighted to witness the continued unlocking of our respiratory franchise in the US with market share expansion in Albuterol and strengthening of the portfolio with Arformoterol launch. Our South Africa private business continues to outperform the market. Our investments in creating a differentiated API portfolio have helped drive growth in the quarter."